OraSure Technologies, Inc. (OSUR) 10-Year Financial Performance & Capital Metrics

OSUR • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

AboutOraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.Show more

Revenue $186M -54.2%
EBITDA -$18M -133.5%
Net Income -$20M -136.3%
EPS (Diluted) -0.26 -136.1%
Gross Margin 42.72% -3.5%
EBITDA Margin -9.66% -173.0%
Operating Margin -15.2% -288.6%
Net Margin -10.49% -179.3%
ROE -4.64% -134.4%
ROIC -13.63% -224.2%
Debt/Equity 0.04 +13.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak 3Y average ROE of 1.4%
✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.73%

5Y3.75%

3Y-7.35%

TTM-43.95%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-629.95%

EPS CAGR

10Y-

5Y-

3Y-

TTM-623.56%

ROCE

10Y Avg4.24%

5Y Avg-1.62%

3Y Avg-1.38%

Latest-6.35%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	119.72M	128.2M	167.06M	181.74M	154.6M	171.72M	233.67M	387.48M	405.47M	185.83M
Revenue Growth %	0.12%	0.07%	0.3%	0.09%	-0.15%	0.11%	0.36%	0.66%	0.05%	-0.54%
Cost of Goods Sold+	39.43M	40.17M	68.11M	68.13M	60.02M	69.85M	116.07M	239.04M	226.05M	106.44M
COGS % of Revenue	0.33%	0.31%	0.41%	0.37%	0.39%	0.41%	0.5%	0.62%	0.56%	0.57%
Gross Profit+	80.29M	88.03M	98.96M	113.61M	94.58M	101.87M	117.6M	148.44M	179.42M	79.39M
Gross Margin %	0.67%	0.69%	0.59%	0.63%	0.61%	0.59%	0.5%	0.38%	0.44%	0.43%
Gross Profit Growth %	0.21%	0.1%	0.12%	0.15%	-0.17%	0.08%	0.15%	0.26%	0.21%	-0.56%
Operating Expenses+	72.23M	67.76M	71.22M	85.18M	75.97M	107.05M	127.76M	170.59M	146.74M	107.64M
OpEx % of Revenue	0.6%	0.53%	0.43%	0.47%	0.49%	0.62%	0.55%	0.44%	0.36%	0.58%
Selling, General & Admin	60.58M	58.01M	57.85M	68.93M	67.16M	77.11M	95.08M	117.44M	92.18M	77.2M
SG&A % of Revenue	0.51%	0.45%	0.35%	0.38%	0.43%	0.45%	0.41%	0.3%	0.23%	0.42%
Research & Development	11.65M	9.75M	13.37M	16.25M	19.63M	31.03M	34.17M	36.24M	33.73M	26.05M
R&D % of Revenue	0.1%	0.08%	0.08%	0.09%	0.13%	0.18%	0.15%	0.09%	0.08%	0.14%
Other Operating Expenses	0	58K	0	0	-10.81M	-1.1M	-1.49M	16.91M	20.83M	4.39M
Operating Income+	8.06M	20.27M	40.24M	28.43M	18.61M	-5.18M	-10.16M	-22.16M	32.68M	-28.25M
Operating Margin %	0.07%	0.16%	0.24%	0.16%	0.12%	-0.03%	-0.04%	-0.06%	0.08%	-0.15%
Operating Income Growth %	2.68%	1.51%	0.99%	-0.29%	-0.35%	-1.28%	-0.96%	-1.18%	2.48%	-1.86%
EBITDA+	13.75M	25.95M	46.64M	34.88M	26.34M	4.54M	2.33M	-6.62M	53.62M	-17.94M
EBITDA Margin %	0.11%	0.2%	0.28%	0.19%	0.17%	0.03%	0.01%	-0.02%	0.13%	-0.1%
EBITDA Growth %	8.14%	0.89%	0.8%	-0.25%	-0.24%	-0.83%	-0.49%	-3.84%	9.1%	-1.33%
D&A (Non-Cash Add-back)	5.7M	5.69M	6.4M	6.45M	7.73M	9.71M	12.49M	15.54M	20.94M	10.31M
EBIT	8.83M	20.27M	27.74M	28.43M	7.8M	-6.28M	-11.65M	-5.24M	43.41M	-23.86M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	774K	58K	794K	3.29M	2.72M	1.65M	872K	6.48M	23.57M	10.55M
Pretax Income+	8.83M	20.32M	41.03M	31.72M	21.33M	-3.52M	-9.29M	-15.68M	56.26M	-17.7M
Pretax Margin %	0.07%	0.16%	0.25%	0.17%	0.14%	-0.02%	-0.04%	-0.04%	0.14%	-0.1%
Income Tax+	665K	603K	10.08M	11.32M	4.67M	11.4M	13.71M	1.46M	2.6M	1.8M
Effective Tax Rate %	0.92%	0.97%	0.75%	0.64%	0.78%	4.23%	2.48%	1.09%	0.95%	1.1%
Net Income+	8.17M	19.72M	30.95M	20.4M	16.66M	-14.92M	-23M	-17.13M	53.66M	-19.5M
Net Margin %	0.07%	0.15%	0.19%	0.11%	0.11%	-0.09%	-0.1%	-0.04%	0.13%	-0.1%
Net Income Growth %	2.77%	1.41%	0.57%	-0.34%	-0.18%	-1.9%	-0.54%	0.26%	4.13%	-1.36%
Net Income (Continuing)	8.17M	19.72M	30.95M	20.4M	16.66M	-14.92M	-23M	-17.13M	53.66M	-19.5M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.14	0.35	0.51	0.33	0.27	-0.22	-0.32	-0.25	0.72	-0.26
EPS Growth %	2.7%	1.5%	0.46%	-0.35%	-0.18%	-1.81%	-0.45%	0.22%	3.88%	-1.36%
EPS (Basic)	0.14	0.35	0.52	0.33	0.27	-0.22	-0.32	-0.25	0.73	-0.26
Diluted Shares Outstanding	56.85M	56.51M	61.02M	62.53M	62.17M	67.5M	71.98M	72.5M	74.39M	74.43M
Basic Shares Outstanding	56.4M	55.62M	59.05M	61.11M	61.67M	67.5M	71.98M	72.5M	73.35M	74.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	136.71M	156.44M	221.91M	219.31M	224.55M	288.89M	299.31M	325.19M	386.46M	333.22M
Cash & Short-Term Investments	101.32M	120.95M	155.9M	156.57M	156.34M	209.4M	153.04M	110.85M	290.41M	267.76M
Cash Only	94.09M	109.79M	72.87M	88.44M	75.72M	160.8M	116.76M	83.98M	290.41M	267.76M
Short-Term Investments	7.22M	11.16M	83.03M	68.13M	80.62M	48.6M	36.28M	26.87M	0	0
Accounts Receivable	19.27M	19.83M	42.52M	34.84M	36.95M	38.84M	45.32M	70.8M	40.17M	23.82M
Days Sales Outstanding	58.74	56.45	92.9	69.97	87.23	82.55	70.79	66.69	36.16	46.78
Inventory	13.24M	11.8M	19.34M	22.89M	23.16M	31.86M	53.14M	95.7M	47.61M	34.2M
Days Inventory Outstanding	122.59	107.21	103.66	122.62	140.81	166.49	167.09	146.13	76.88	117.27
Other Current Assets	1.35M	3.97M	4.33M	3.08M	5.68M	4.93M	39.87M	41.57M	2.23M	3.49M
Total Non-Current Assets+	52.61M	51.49M	74.3M	96.26M	124.75M	165.58M	161.68M	118.99M	96.39M	146.44M
Property, Plant & Equipment	20.08M	20.03M	21.37M	24.3M	37.29M	57.63M	84.98M	71.11M	58.27M	58.69M
Fixed Asset Turnover	5.96x	6.40x	7.82x	7.48x	4.15x	2.98x	2.75x	5.45x	6.96x	3.17x
Goodwill	18.25M	18.79M	20.08M	18.52M	36.2M	40.35M	40.28M	35.1M	35.7M	40.33M
Intangible Assets	12.59M	10.34M	8.22M	5.14M	14.67M	17.9M	14.34M	11.69M	1.21M	17.43M
Long-Term Investments	-2.88M	-2.45M	20.69M	44.75M	33.42M	47.72M	17.01M	0	0	28.3M
Other Non-Current Assets	1.68M	2.33M	1.98M	3.55M	3.16M	1.97M	5.07M	1.09M	1.22M	1.53M
Total Assets+	189.32M	207.94M	296.2M	315.57M	349.3M	454.47M	460.99M	444.18M	482.85M	479.66M
Asset Turnover	0.63x	0.62x	0.56x	0.58x	0.44x	0.38x	0.51x	0.87x	0.84x	0.39x
Asset Growth %	-0%	0.1%	0.42%	0.07%	0.11%	0.3%	0.01%	-0.04%	0.09%	-0.01%
Total Current Liabilities+	25.23M	17.34M	32.24M	27.98M	32.71M	46.49M	68.06M	69.06M	39.54M	33.48M
Accounts Payable	5.09M	4.59M	10.23M	10.6M	9.57M	17.41M	28.02M	38.02M	13.15M	8.17M
Days Payables Outstanding	47.09	41.74	54.81	56.78	58.18	90.96	88.12	58.05	21.23	28.03
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.27M	1.97M	4.96M	3.49M	8.93M	4.48M	4.75M	5.52M	3.98M	5.22M
Current Ratio	5.42x	9.02x	6.88x	7.84x	6.86x	6.21x	4.40x	4.71x	9.77x	9.95x
Quick Ratio	4.89x	8.34x	6.28x	7.02x	6.16x	5.53x	3.62x	3.32x	8.57x	8.93x
Cash Conversion Cycle	134.23	121.92	141.75	135.82	169.86	158.08	149.77	154.77	91.81	136.02
Total Non-Current Liabilities+	4.65M	4.75M	5.88M	4.21M	9.44M	9.41M	12.39M	10.69M	12.64M	35.84M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	5.58M	4.49M	9.15M	9.6M	11.39M	12.43M
Deferred Tax Liabilities	2.88M	2.45M	1.95M	3.31M	899K	1.2M	2.23M	408K	554K	0
Other Non-Current Liabilities	1.77M	2.3M	3.93M	0	2.96M	3.73M	1M	680K	696K	23.4M
Total Liabilities	29.89M	22.09M	38.12M	32.19M	42.15M	55.9M	80.46M	79.75M	52.17M	69.32M
Total Debt+	0	0	0	0	7.22M	6.13M	12.27M	12.55M	13.5M	14.6M
Net Debt	-94.09M	-109.79M	-72.87M	-88.44M	-68.49M	-154.67M	-104.49M	-71.43M	-276.9M	-253.16M
Debt / Equity	-	-	-	-	0.02x	0.02x	0.03x	0.03x	0.03x	0.04x
Debt / EBITDA	-	-	-	-	0.27x	1.35x	5.27x	-	0.25x	-
Net Debt / EBITDA	-6.84x	-4.23x	-1.56x	-2.54x	-2.60x	-34.09x	-44.83x	-	-5.16x	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	159.44M	185.85M	258.08M	283.38M	307.14M	398.57M	380.53M	364.43M	430.67M	410.34M
Equity Growth %	0%	0.17%	0.39%	0.1%	0.08%	0.3%	-0.05%	-0.04%	0.18%	-0.05%
Book Value per Share	2.80	3.29	4.23	4.53	4.94	5.90	5.29	5.03	5.79	5.51
Total Shareholders' Equity	159.44M	185.85M	258.08M	283.38M	307.14M	398.57M	380.53M	364.43M	430.67M	410.34M
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-170.18M	-150.46M	-119.51M	-99.19M	-82.53M	-97.45M	-120.45M	-137.59M	-83.93M	-103.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-15.64M	-14.22M	-10.34M	-18.71M	-12.14M	-9.1M	-10.08M	-18.43M	-14.94M	-24.36M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	15.77M	22.77M	28.16M	39.09M	9.8M	5.81M	-35.38M	-47.2M	141.58M	27.37M
Operating CF Margin %	0.13%	0.18%	0.17%	0.22%	0.06%	0.03%	-0.15%	-0.12%	0.35%	0.15%
Operating CF Growth %	1.1%	0.44%	0.24%	0.39%	-0.75%	-0.41%	-7.09%	-0.33%	4%	-0.81%
Net Income	8.17M	19.72M	30.95M	20.4M	16.66M	-14.92M	-23M	-17.93M	53.66M	-19.5M
Depreciation & Amortization	5.7M	5.69M	6.4M	7.22M	7.73M	9.71M	12.49M	15.54M	20.94M	10.87M
Stock-Based Compensation	6.05M	6.06M	6.97M	15.24M	4.06M	7.14M	7.81M	11.62M	10.73M	11.92M
Deferred Taxes	48K	-529K	-649K	-919K	-1.46M	-392K	1.03M	-1.65M	102K	-657K
Other Non-Cash Items	556K	47K	131K	-400K	-8.28M	-424K	4.72M	15.79M	10.4M	5.92M
Working Capital Changes	-4.74M	-8.22M	-15.65M	-2.45M	-8.9M	4.69M	-38.44M	-70.56M	45.76M	18.82M
Change in Receivables	-3.74M	-576K	-22.12M	6.63M	-2.21M	-2.32M	-6.45M	-25.16M	31.12M	15.87M
Change in Inventory	2.35M	1.48M	-7.39M	-3.86M	-1.04M	-8.61M	-27.94M	-43.05M	48.23M	13.1M
Change in Payables	-2.65M	46K	5.16M	208K	-1.54M	7.38M	3.23M	3.96M	-26.98M	-7.58M
Cash from Investing+	-6.71M	-8.06M	-96.35M	-17.43M	-19.8M	-14.03M	-5.5M	21.09M	66.15M	-39.03M
Capital Expenditures	-3.74M	-4.35M	-4.34M	-6.34M	-9.31M	-28.92M	-48.12M	-63.91M	-10.3M	-3.8M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.03%	0.06%	0.17%	0.21%	0.16%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.96M	-3.71M	-92.02M	-11.08M	0	351K	513K	60.33M	48.67M	-30M
Cash from Financing+	-5.69M	-1.16M	30.43M	-1.89M	-4.68M	92.48M	-2.82M	-3.83M	-3.02M	-4.18M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	404K	2.29M	31.68M	1.7M	196K	218K	-18K	-193K	223K	214K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	12.03M	18.41M	23.82M	32.75M	490K	-23.12M	-83.5M	-111.11M	131.28M	23.58M
FCF Margin %	0.1%	0.14%	0.14%	0.18%	0%	-0.13%	-0.36%	-0.29%	0.32%	0.13%
FCF Growth %	1.66%	0.53%	0.29%	0.37%	-0.99%	-48.18%	-2.61%	-0.33%	2.18%	-0.82%
FCF per Share	0.21	0.33	0.39	0.52	0.01	-0.34	-1.16	-1.53	1.76	0.32
FCF Conversion (FCF/Net Income)	1.93x	1.15x	0.91x	1.92x	0.59x	-0.39x	1.54x	2.76x	2.64x	-1.40x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.13%	11.42%	13.94%	7.53%	5.64%	-4.23%	-5.9%	-4.6%	13.5%	-4.64%
Return on Invested Capital (ROIC)	9.21%	21.5%	23.1%	11.22%	6.44%	-1.61%	-2.93%	-5.84%	10.97%	-13.63%
Gross Margin	67.07%	68.66%	59.23%	62.51%	61.18%	59.32%	50.33%	38.31%	44.25%	42.72%
Net Margin	6.82%	15.38%	18.52%	11.22%	10.77%	-8.69%	-9.84%	-4.42%	13.23%	-10.49%
Debt / Equity	-	-	-	-	0.02x	0.02x	0.03x	0.03x	0.03x	0.04x
FCF Conversion	1.93x	1.15x	0.91x	1.92x	0.59x	-0.39x	1.54x	2.76x	2.64x	-1.40x
Revenue Growth	12.45%	7.08%	30.32%	8.79%	-14.93%	11.07%	36.08%	65.82%	4.64%	-54.17%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product And Services	-	-	-	-	148.07M	166.38M	226.9M	378.05M	402.22M	184.61M
Product And Services Growth	-	-	-	-	-	12.36%	36.37%	66.62%	6.39%	-54.10%
Other Revenues	-	-	-	-	6.53M	5.34M	6.78M	9.43M	3.25M	1.22M
Other Revenues Growth	-	-	-	-	-	-18.25%	26.91%	39.18%	-65.54%	-62.58%
Ora Quick Hiv Self Test	-	-	-	4.43M	-	-	-	-	-	-
Ora Quick Hiv Self Test Growth	-	-	-	-	-	-	-	-	-	-
Ora Quick HIV Self Test	-	-	1.05M	-	-	-	-	-	-	-
Ora Quick HIV Self Test Growth	-	-	-	-	-	-	-	-	-	-
OSUR	89.8M	95.98M	-	-	-	-	-	-	-	-
OSUR Growth	-	6.89%	-	-	-	-	-	-	-	-
DNAG	29.92M	32.21M	-	-	-	-	-	-	-	-
DNAG Growth	-	7.65%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	96.52M	99.76M	121.46M	136.85M	107.28M	130.84M	188.38M	350.21M	361.66M	139.16M
UNITED STATES Growth	-	3.35%	21.75%	12.67%	-21.61%	21.96%	43.99%	85.90%	3.27%	-61.52%
Africa	-	-	-	-	-	-	-	-	-	32.74M
Africa Growth	-	-	-	-	-	-	-	-	-	-
Europe	13.54M	11.65M	11.83M	11.06M	11.75M	12.07M	13.8M	11.54M	8.11M	8.42M
Europe Growth	-	-13.96%	1.55%	-6.47%	6.24%	2.69%	14.34%	-16.40%	-29.69%	3.86%
Other Foreign Countries	9.66M	16.79M	33.78M	33.83M	35.57M	28.82M	31.49M	25.74M	35.7M	5.5M
Other Foreign Countries Growth	-	73.81%	101.14%	0.16%	5.14%	-18.99%	9.28%	-18.27%	38.71%	-84.60%

Frequently Asked Questions

Growth & Financials

OraSure Technologies, Inc. (OSUR) reported $125.7M in revenue for fiscal year 2024. This represents a 54% increase from $81.9M in 2011.

OraSure Technologies, Inc. (OSUR) saw revenue decline by 54.2% over the past year.

OraSure Technologies, Inc. (OSUR) reported a net loss of $60.2M for fiscal year 2024.

Dividend & Returns

OraSure Technologies, Inc. (OSUR) has a return on equity (ROE) of -4.6%. Negative ROE indicates the company is unprofitable.

OraSure Technologies, Inc. (OSUR) had negative free cash flow of $43.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

OraSure Technologies, Inc. (OSUR) 10-Year Financial Performance & Capital Metrics

OSUR • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

Revenue $186M -54.2%
EBITDA -$18M -133.5%
Net Income -$20M -136.3%
EPS (Diluted) -0.26 -136.1%
Gross Margin 42.72% -3.5%
EBITDA Margin -9.66% -173.0%
Operating Margin -15.2% -288.6%
Net Margin -10.49% -179.3%
ROE -4.64% -134.4%
ROIC -13.63% -224.2%
Debt/Equity 0.04 +13.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Trading at only 0.5x book value

✗Weaknesses

✗Weak 3Y average ROE of 1.4%
✗Weak Piotroski F-Score: 3/9
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.73%

5Y3.75%

3Y-7.35%

TTM-43.95%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-629.95%

EPS CAGR

10Y-

5Y-

3Y-

TTM-623.56%

ROCE

10Y Avg4.24%

5Y Avg-1.62%

3Y Avg-1.38%

Latest-6.35%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	119.72M	128.2M	167.06M	181.74M	154.6M	171.72M	233.67M	387.48M	405.47M	185.83M
Revenue Growth %	0.12%	0.07%	0.3%	0.09%	-0.15%	0.11%	0.36%	0.66%	0.05%	-0.54%
Cost of Goods Sold+	39.43M	40.17M	68.11M	68.13M	60.02M	69.85M	116.07M	239.04M	226.05M	106.44M
COGS % of Revenue	0.33%	0.31%	0.41%	0.37%	0.39%	0.41%	0.5%	0.62%	0.56%	0.57%
Gross Profit+	80.29M	88.03M	98.96M	113.61M	94.58M	101.87M	117.6M	148.44M	179.42M	79.39M
Gross Margin %	0.67%	0.69%	0.59%	0.63%	0.61%	0.59%	0.5%	0.38%	0.44%	0.43%
Gross Profit Growth %	0.21%	0.1%	0.12%	0.15%	-0.17%	0.08%	0.15%	0.26%	0.21%	-0.56%
Operating Expenses+	72.23M	67.76M	71.22M	85.18M	75.97M	107.05M	127.76M	170.59M	146.74M	107.64M
OpEx % of Revenue	0.6%	0.53%	0.43%	0.47%	0.49%	0.62%	0.55%	0.44%	0.36%	0.58%
Selling, General & Admin	60.58M	58.01M	57.85M	68.93M	67.16M	77.11M	95.08M	117.44M	92.18M	77.2M
SG&A % of Revenue	0.51%	0.45%	0.35%	0.38%	0.43%	0.45%	0.41%	0.3%	0.23%	0.42%
Research & Development	11.65M	9.75M	13.37M	16.25M	19.63M	31.03M	34.17M	36.24M	33.73M	26.05M
R&D % of Revenue	0.1%	0.08%	0.08%	0.09%	0.13%	0.18%	0.15%	0.09%	0.08%	0.14%
Other Operating Expenses	0	58K	0	0	-10.81M	-1.1M	-1.49M	16.91M	20.83M	4.39M
Operating Income+	8.06M	20.27M	40.24M	28.43M	18.61M	-5.18M	-10.16M	-22.16M	32.68M	-28.25M
Operating Margin %	0.07%	0.16%	0.24%	0.16%	0.12%	-0.03%	-0.04%	-0.06%	0.08%	-0.15%
Operating Income Growth %	2.68%	1.51%	0.99%	-0.29%	-0.35%	-1.28%	-0.96%	-1.18%	2.48%	-1.86%
EBITDA+	13.75M	25.95M	46.64M	34.88M	26.34M	4.54M	2.33M	-6.62M	53.62M	-17.94M
EBITDA Margin %	0.11%	0.2%	0.28%	0.19%	0.17%	0.03%	0.01%	-0.02%	0.13%	-0.1%
EBITDA Growth %	8.14%	0.89%	0.8%	-0.25%	-0.24%	-0.83%	-0.49%	-3.84%	9.1%	-1.33%
D&A (Non-Cash Add-back)	5.7M	5.69M	6.4M	6.45M	7.73M	9.71M	12.49M	15.54M	20.94M	10.31M
EBIT	8.83M	20.27M	27.74M	28.43M	7.8M	-6.28M	-11.65M	-5.24M	43.41M	-23.86M
Net Interest Income+	0	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	774K	58K	794K	3.29M	2.72M	1.65M	872K	6.48M	23.57M	10.55M
Pretax Income+	8.83M	20.32M	41.03M	31.72M	21.33M	-3.52M	-9.29M	-15.68M	56.26M	-17.7M
Pretax Margin %	0.07%	0.16%	0.25%	0.17%	0.14%	-0.02%	-0.04%	-0.04%	0.14%	-0.1%
Income Tax+	665K	603K	10.08M	11.32M	4.67M	11.4M	13.71M	1.46M	2.6M	1.8M
Effective Tax Rate %	0.92%	0.97%	0.75%	0.64%	0.78%	4.23%	2.48%	1.09%	0.95%	1.1%
Net Income+	8.17M	19.72M	30.95M	20.4M	16.66M	-14.92M	-23M	-17.13M	53.66M	-19.5M
Net Margin %	0.07%	0.15%	0.19%	0.11%	0.11%	-0.09%	-0.1%	-0.04%	0.13%	-0.1%
Net Income Growth %	2.77%	1.41%	0.57%	-0.34%	-0.18%	-1.9%	-0.54%	0.26%	4.13%	-1.36%
Net Income (Continuing)	8.17M	19.72M	30.95M	20.4M	16.66M	-14.92M	-23M	-17.13M	53.66M	-19.5M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	0.14	0.35	0.51	0.33	0.27	-0.22	-0.32	-0.25	0.72	-0.26
EPS Growth %	2.7%	1.5%	0.46%	-0.35%	-0.18%	-1.81%	-0.45%	0.22%	3.88%	-1.36%
EPS (Basic)	0.14	0.35	0.52	0.33	0.27	-0.22	-0.32	-0.25	0.73	-0.26
Diluted Shares Outstanding	56.85M	56.51M	61.02M	62.53M	62.17M	67.5M	71.98M	72.5M	74.39M	74.43M
Basic Shares Outstanding	56.4M	55.62M	59.05M	61.11M	61.67M	67.5M	71.98M	72.5M	73.35M	74.43M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	136.71M	156.44M	221.91M	219.31M	224.55M	288.89M	299.31M	325.19M	386.46M	333.22M
Cash & Short-Term Investments	101.32M	120.95M	155.9M	156.57M	156.34M	209.4M	153.04M	110.85M	290.41M	267.76M
Cash Only	94.09M	109.79M	72.87M	88.44M	75.72M	160.8M	116.76M	83.98M	290.41M	267.76M
Short-Term Investments	7.22M	11.16M	83.03M	68.13M	80.62M	48.6M	36.28M	26.87M	0	0
Accounts Receivable	19.27M	19.83M	42.52M	34.84M	36.95M	38.84M	45.32M	70.8M	40.17M	23.82M
Days Sales Outstanding	58.74	56.45	92.9	69.97	87.23	82.55	70.79	66.69	36.16	46.78
Inventory	13.24M	11.8M	19.34M	22.89M	23.16M	31.86M	53.14M	95.7M	47.61M	34.2M
Days Inventory Outstanding	122.59	107.21	103.66	122.62	140.81	166.49	167.09	146.13	76.88	117.27
Other Current Assets	1.35M	3.97M	4.33M	3.08M	5.68M	4.93M	39.87M	41.57M	2.23M	3.49M
Total Non-Current Assets+	52.61M	51.49M	74.3M	96.26M	124.75M	165.58M	161.68M	118.99M	96.39M	146.44M
Property, Plant & Equipment	20.08M	20.03M	21.37M	24.3M	37.29M	57.63M	84.98M	71.11M	58.27M	58.69M
Fixed Asset Turnover	5.96x	6.40x	7.82x	7.48x	4.15x	2.98x	2.75x	5.45x	6.96x	3.17x
Goodwill	18.25M	18.79M	20.08M	18.52M	36.2M	40.35M	40.28M	35.1M	35.7M	40.33M
Intangible Assets	12.59M	10.34M	8.22M	5.14M	14.67M	17.9M	14.34M	11.69M	1.21M	17.43M
Long-Term Investments	-2.88M	-2.45M	20.69M	44.75M	33.42M	47.72M	17.01M	0	0	28.3M
Other Non-Current Assets	1.68M	2.33M	1.98M	3.55M	3.16M	1.97M	5.07M	1.09M	1.22M	1.53M
Total Assets+	189.32M	207.94M	296.2M	315.57M	349.3M	454.47M	460.99M	444.18M	482.85M	479.66M
Asset Turnover	0.63x	0.62x	0.56x	0.58x	0.44x	0.38x	0.51x	0.87x	0.84x	0.39x
Asset Growth %	-0%	0.1%	0.42%	0.07%	0.11%	0.3%	0.01%	-0.04%	0.09%	-0.01%
Total Current Liabilities+	25.23M	17.34M	32.24M	27.98M	32.71M	46.49M	68.06M	69.06M	39.54M	33.48M
Accounts Payable	5.09M	4.59M	10.23M	10.6M	9.57M	17.41M	28.02M	38.02M	13.15M	8.17M
Days Payables Outstanding	47.09	41.74	54.81	56.78	58.18	90.96	88.12	58.05	21.23	28.03
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	2.27M	1.97M	4.96M	3.49M	8.93M	4.48M	4.75M	5.52M	3.98M	5.22M
Current Ratio	5.42x	9.02x	6.88x	7.84x	6.86x	6.21x	4.40x	4.71x	9.77x	9.95x
Quick Ratio	4.89x	8.34x	6.28x	7.02x	6.16x	5.53x	3.62x	3.32x	8.57x	8.93x
Cash Conversion Cycle	134.23	121.92	141.75	135.82	169.86	158.08	149.77	154.77	91.81	136.02
Total Non-Current Liabilities+	4.65M	4.75M	5.88M	4.21M	9.44M	9.41M	12.39M	10.69M	12.64M	35.84M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	5.58M	4.49M	9.15M	9.6M	11.39M	12.43M
Deferred Tax Liabilities	2.88M	2.45M	1.95M	3.31M	899K	1.2M	2.23M	408K	554K	0
Other Non-Current Liabilities	1.77M	2.3M	3.93M	0	2.96M	3.73M	1M	680K	696K	23.4M
Total Liabilities	29.89M	22.09M	38.12M	32.19M	42.15M	55.9M	80.46M	79.75M	52.17M	69.32M
Total Debt+	0	0	0	0	7.22M	6.13M	12.27M	12.55M	13.5M	14.6M
Net Debt	-94.09M	-109.79M	-72.87M	-88.44M	-68.49M	-154.67M	-104.49M	-71.43M	-276.9M	-253.16M
Debt / Equity	-	-	-	-	0.02x	0.02x	0.03x	0.03x	0.03x	0.04x
Debt / EBITDA	-	-	-	-	0.27x	1.35x	5.27x	-	0.25x	-
Net Debt / EBITDA	-6.84x	-4.23x	-1.56x	-2.54x	-2.60x	-34.09x	-44.83x	-	-5.16x	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	159.44M	185.85M	258.08M	283.38M	307.14M	398.57M	380.53M	364.43M	430.67M	410.34M
Equity Growth %	0%	0.17%	0.39%	0.1%	0.08%	0.3%	-0.05%	-0.04%	0.18%	-0.05%
Book Value per Share	2.80	3.29	4.23	4.53	4.94	5.90	5.29	5.03	5.79	5.51
Total Shareholders' Equity	159.44M	185.85M	258.08M	283.38M	307.14M	398.57M	380.53M	364.43M	430.67M	410.34M
Common Stock	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-170.18M	-150.46M	-119.51M	-99.19M	-82.53M	-97.45M	-120.45M	-137.59M	-83.93M	-103.43M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-15.64M	-14.22M	-10.34M	-18.71M	-12.14M	-9.1M	-10.08M	-18.43M	-14.94M	-24.36M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	15.77M	22.77M	28.16M	39.09M	9.8M	5.81M	-35.38M	-47.2M	141.58M	27.37M
Operating CF Margin %	0.13%	0.18%	0.17%	0.22%	0.06%	0.03%	-0.15%	-0.12%	0.35%	0.15%
Operating CF Growth %	1.1%	0.44%	0.24%	0.39%	-0.75%	-0.41%	-7.09%	-0.33%	4%	-0.81%
Net Income	8.17M	19.72M	30.95M	20.4M	16.66M	-14.92M	-23M	-17.93M	53.66M	-19.5M
Depreciation & Amortization	5.7M	5.69M	6.4M	7.22M	7.73M	9.71M	12.49M	15.54M	20.94M	10.87M
Stock-Based Compensation	6.05M	6.06M	6.97M	15.24M	4.06M	7.14M	7.81M	11.62M	10.73M	11.92M
Deferred Taxes	48K	-529K	-649K	-919K	-1.46M	-392K	1.03M	-1.65M	102K	-657K
Other Non-Cash Items	556K	47K	131K	-400K	-8.28M	-424K	4.72M	15.79M	10.4M	5.92M
Working Capital Changes	-4.74M	-8.22M	-15.65M	-2.45M	-8.9M	4.69M	-38.44M	-70.56M	45.76M	18.82M
Change in Receivables	-3.74M	-576K	-22.12M	6.63M	-2.21M	-2.32M	-6.45M	-25.16M	31.12M	15.87M
Change in Inventory	2.35M	1.48M	-7.39M	-3.86M	-1.04M	-8.61M	-27.94M	-43.05M	48.23M	13.1M
Change in Payables	-2.65M	46K	5.16M	208K	-1.54M	7.38M	3.23M	3.96M	-26.98M	-7.58M
Cash from Investing+	-6.71M	-8.06M	-96.35M	-17.43M	-19.8M	-14.03M	-5.5M	21.09M	66.15M	-39.03M
Capital Expenditures	-3.74M	-4.35M	-4.34M	-6.34M	-9.31M	-28.92M	-48.12M	-63.91M	-10.3M	-3.8M
CapEx % of Revenue	0.03%	0.03%	0.03%	0.03%	0.06%	0.17%	0.21%	0.16%	0.03%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2.96M	-3.71M	-92.02M	-11.08M	0	351K	513K	60.33M	48.67M	-30M
Cash from Financing+	-5.69M	-1.16M	30.43M	-1.89M	-4.68M	92.48M	-2.82M	-3.83M	-3.02M	-4.18M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	404K	2.29M	31.68M	1.7M	196K	218K	-18K	-193K	223K	214K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	12.03M	18.41M	23.82M	32.75M	490K	-23.12M	-83.5M	-111.11M	131.28M	23.58M
FCF Margin %	0.1%	0.14%	0.14%	0.18%	0%	-0.13%	-0.36%	-0.29%	0.32%	0.13%
FCF Growth %	1.66%	0.53%	0.29%	0.37%	-0.99%	-48.18%	-2.61%	-0.33%	2.18%	-0.82%
FCF per Share	0.21	0.33	0.39	0.52	0.01	-0.34	-1.16	-1.53	1.76	0.32
FCF Conversion (FCF/Net Income)	1.93x	1.15x	0.91x	1.92x	0.59x	-0.39x	1.54x	2.76x	2.64x	-1.40x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	5.13%	11.42%	13.94%	7.53%	5.64%	-4.23%	-5.9%	-4.6%	13.5%	-4.64%
Return on Invested Capital (ROIC)	9.21%	21.5%	23.1%	11.22%	6.44%	-1.61%	-2.93%	-5.84%	10.97%	-13.63%
Gross Margin	67.07%	68.66%	59.23%	62.51%	61.18%	59.32%	50.33%	38.31%	44.25%	42.72%
Net Margin	6.82%	15.38%	18.52%	11.22%	10.77%	-8.69%	-9.84%	-4.42%	13.23%	-10.49%
Debt / Equity	-	-	-	-	0.02x	0.02x	0.03x	0.03x	0.03x	0.04x
FCF Conversion	1.93x	1.15x	0.91x	1.92x	0.59x	-0.39x	1.54x	2.76x	2.64x	-1.40x
Revenue Growth	12.45%	7.08%	30.32%	8.79%	-14.93%	11.07%	36.08%	65.82%	4.64%	-54.17%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product And Services	-	-	-	-	148.07M	166.38M	226.9M	378.05M	402.22M	184.61M
Product And Services Growth	-	-	-	-	-	12.36%	36.37%	66.62%	6.39%	-54.10%
Other Revenues	-	-	-	-	6.53M	5.34M	6.78M	9.43M	3.25M	1.22M
Other Revenues Growth	-	-	-	-	-	-18.25%	26.91%	39.18%	-65.54%	-62.58%
Ora Quick Hiv Self Test	-	-	-	4.43M	-	-	-	-	-	-
Ora Quick Hiv Self Test Growth	-	-	-	-	-	-	-	-	-	-
Ora Quick HIV Self Test	-	-	1.05M	-	-	-	-	-	-	-
Ora Quick HIV Self Test Growth	-	-	-	-	-	-	-	-	-	-
OSUR	89.8M	95.98M	-	-	-	-	-	-	-	-
OSUR Growth	-	6.89%	-	-	-	-	-	-	-	-
DNAG	29.92M	32.21M	-	-	-	-	-	-	-	-
DNAG Growth	-	7.65%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	96.52M	99.76M	121.46M	136.85M	107.28M	130.84M	188.38M	350.21M	361.66M	139.16M
UNITED STATES Growth	-	3.35%	21.75%	12.67%	-21.61%	21.96%	43.99%	85.90%	3.27%	-61.52%
Africa	-	-	-	-	-	-	-	-	-	32.74M
Africa Growth	-	-	-	-	-	-	-	-	-	-
Europe	13.54M	11.65M	11.83M	11.06M	11.75M	12.07M	13.8M	11.54M	8.11M	8.42M
Europe Growth	-	-13.96%	1.55%	-6.47%	6.24%	2.69%	14.34%	-16.40%	-29.69%	3.86%
Other Foreign Countries	9.66M	16.79M	33.78M	33.83M	35.57M	28.82M	31.49M	25.74M	35.7M	5.5M
Other Foreign Countries Growth	-	73.81%	101.14%	0.16%	5.14%	-18.99%	9.28%	-18.27%	38.71%	-84.60%

Frequently Asked Questions

Growth & Financials

OraSure Technologies, Inc. (OSUR) reported $125.7M in revenue for fiscal year 2024. This represents a 54% increase from $81.9M in 2011.

OraSure Technologies, Inc. (OSUR) saw revenue decline by 54.2% over the past year.

OraSure Technologies, Inc. (OSUR) reported a net loss of $60.2M for fiscal year 2024.

Dividend & Returns

OraSure Technologies, Inc. (OSUR) has a return on equity (ROE) of -4.6%. Negative ROE indicates the company is unprofitable.

OraSure Technologies, Inc. (OSUR) had negative free cash flow of $43.6M in fiscal year 2024, likely due to heavy capital investments.